ClinicalTrials.gg
RecruitingNCT04730622Updated May 22, 2026

Study of Parameters of Osteosarcopenia in Patients With Hip Fracture

An observational study in Osteoporotic Fracture of Femur and Osteoarthritis, Hip, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Istituto Ortopedico Rizzoli · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Hip · Istituto Ortopedico Rizzoli.

Started
2020
the only one that year
Observational
4 of 13
1 open now
Registered
7th of 13
by date

Among the 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli, this one is the only one that started in 2020, is one of 4 observational ones, and was the 7th registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

3 of the 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli, or all of them as a file.
02

Study summary

The study aims to assess the adequacy of a set of clinical and laboratory investigations for identifying the osteosarcopenia status in patients undergoing a hip replacement for a fragility fracture of the femoral neck. The control group will consist of patients undergoing a hip replacement for osteoarthritis, as the decrease in muscle function and bone quality is less severe in this condition than in osteoporosis.

Read the detailed description

Osteoporotic hip fractures (fragility fractures) are common in older adults, and the risk of adverse outcomes and mortality is higher in patients affected by osteosarcopenia, a geriatric syndrome in which the low bone mineral density and bone microarchitecture deterioration (osteopenia/osteoporosis) are combined with a decline in mass, strength, and functional capacity of skeletal muscle (sarcopenia).

The diagnostic workup currently recommended to establish the severity of osteosarcopenia is hard to implement in individuals who arrive at the orthopedic emergency department with a fragility fracture. On the one hand, the evaluation of motility and physical performance is impracticable in bedridden patients; on the other hand, the surgical treatment priority does not allow performing all the instrumental investigations required for a proper diagnosis. In this context, reliable osteosarcopenia biomarkers could help identify most frail patients and plan for them personalized therapeutic interventions to promote postoperative recovery and reduce the risk of adverse outcomes.

Based on the new knowledge on the pathophysiology of osteosarcopenia, the investigators designed a small-scale study that aims to preliminarily verify the adequacy of a set of clinical and laboratory parameters that could be easily applied in hospitalized patients undergoing hip replacement for a fragility fracture. In particular, the investigators planned to assess the following:

  • muscle performance by SARC-F questionnaire (acronym deriving from five domains considered in the questionnaire, i.e., strength, assistance with walking, rising from a chair, climbing stairs, and falls);
  • dietary habits through a questionnaire on the intake frequency of food categories;
  • histological features of osteoporosis and sarcopenia in tissue samples taken from the surgical site;
  • the serum levels of markers associated with muscle-bone cross-talk (Myostatin, Insulin-like growth factor 1);
  • the serum levels of the following pro-inflammatory cytokines to get a clearer picture of the presence of the inflammatory state: IL-6, IL-8, TNF-α;
  • the serum levels of markers such as FGF-21, GDF15, soluble ST2, interesting markers of bone metabolism, indicators of bone mineral density, and modulators of osteoblast-osteoclast activity;
  • the composition of the gut microbiota.

The study includes 100 patients who are candidates for hip replacement surgery (endo- and arthroplasty). As the decrease in muscle function and bone quality is more severe in fragility fractures than in osteoarthritis, the investigators expect to find differences in laboratory and clinical parameters.

03

Conditions studied

  • Osteoporotic Fracture of Femur
  • Osteoarthritis, Hip

Keywords

  • Osteoporosis
  • Sarcopenia
  • Hip prosthesis
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized patients admitted at the 1st Orthopaedic and Traumatology Unit of the Istituto Ortopedico Rizzoli (Bologna, Italy).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who came to observation with femoral neck fracture of possible osteoporotic nature (no or minimal trauma) to be treated with endoprosthesis or hip arthroplasty.
  • Competent patients who have signed consent to participate in the study (see section of this protocol).

Exclusion criteria

Exclusion Criteria:

  • Previous osteoporotic fractures
  • Previous prosthetic surgery for orthopedic diseases
  • Pre-existing clinical conditions that led to permanent immobility
  • Neoplastic diseases
  • diseases
  • Severe myopathies
  • Chronic viral infections (, , );
  • Chronic treatment with anti-osteoporotic drugs, drugs, and insulin
  • Paget's disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Fragility fracture

    Patients who are candidates for hip replacement surgery (endo- and arthroplasty).

    Diagnostic Test: SARC-F questionnaire · Diagnostic Test: Bone tissue histology · Diagnostic Test: Muscle tissue histology · Diagnostic Test: Myostatin serum levels · Diagnostic Test: Insulin-like growth factor 1 (IGF-1) serum levels · Other: Frequency food questionnaire · Other: Gut microbiota profiling

Interventions

  • Diagnostic testSARC-F questionnaire

    Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.

  • Diagnostic testBone tissue histology

    Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.

  • Diagnostic testMuscle tissue histology

    Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.

  • Diagnostic testMyostatin serum levels

    Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.

  • Diagnostic testInsulin-like growth factor 1 (IGF-1) serum levels

    Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.

  • OtherFrequency food questionnaire

    Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.

  • OtherGut microbiota profiling

    Assessment of gut microbiome composition on stool samples.

06

What researchers measure

Primary outcomes

  1. Acceptability of the SARC-F questionnaire

    The number of patients able to provide answers divided by the total number of enrolled patients.

    Time frame: Within 24 hours of admission

  2. Frequency of positive SARC-F questionnaire in cases (fragility fractures) and controls (osteoarthritis)

    The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit a positive SARC-F questionnaire. The SARC-F is positive and indicates potential sarcopenia if the score point is = or \> 4. For each component of the questionnaire (grip strength, assistance with walking, rising from a chair, climbing stairs, and falls), the score may be 0 (no difficulty; no falls), 1 (some difficulty), and 2 (a lot of difficulties and falls). The total score may range from 0 to 10.

    Time frame: Within 24 hours of admission

  3. Presence of histological features of osteoporotic bone in cases (fragility fractures) and controls (osteoarthritis)

    The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit histological features of osteoporotic bone. The presence of osteoporotic bone will be proved based on the following histological features: loss of connected trabecular bone, altered matrix mineralization, the prevalence of adipose tissue compared to bone marrow, presence of osteoclasts.

    Time frame: Through study completion, an average of 1 year.

  4. Presence of histological features of muscle atrophy in cases (fragility fractures) and controls (osteoarthritis)

    The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit histological features of muscle atrophy. The presence of muscle atrophy will be proved based on the following histological features: decrease in size and number of type II myofibers, presence of necrosis or fibro-adipose replacement, decrease in satellite cell number.

    Time frame: Through study completion, an average of 1 year.

  5. Myostatin serum levels in cases (fragility fractures) and controls (osteoarthritis)

    The immunoenzymatic quantification of circulating Myostatin (µg/L) will be performed on serum samples obtained from peripheral venous blood. The results will be aggregated as mean ± standard error of the mean, median, and min-max range.

    Time frame: Through study completion, an average of 1 year.

  6. Insulin-like growth factor 1 (IGF-1) serum levels in cases (fragility fractures) and controls (osteoarthritis)

    The immunoenzymatic quantification of circulating IGF-1 (µg/L) will be performed on serum samples obtained from peripheral venous blood. The results will be aggregated as mean ± standard error of the mean, median, and min-max range.

    Time frame: Through study completion, an average of 1 year.

  7. Acceptability of the Frequency Food Questionnaire

    The number of patients able to provide answers divided by the total number of enrolled patients.

    Time frame: Within 24 hours of admission

  8. Frequency of intake of the different food categories in cases (fragility fractures) and controls (osteoarthritis)

    The percentages of cases (fragility fractures) and controls (osteoarthritis) who assume never/rarely or regularly the different food categories.

    Time frame: Within 24 hours of admission

Secondary outcomes

  1. Frequency of positive SARC-F questionnaire in patients with and without osteoporotic bone

    The percentage of patients with and without osteoporotic bone who exhibit a positive (= or \> 4) or negative (\< 4) SARC-F questionnaire.

    Time frame: Through study completion, an average of 1 year.

  2. Frequency of positive SARC-F questionnaire in patients with and without muscle atrophy

    The percentage of patients with and without muscle atrophy who exhibit a positive (= or \> 4) or negative (\< 4) SARC-F questionnaire.

    Time frame: Through study completion, an average of 1 year.

  3. Myostatin serum levels in patients with positive and negative SARC-F questionnaire

    Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with positive (= or \> 4) and negative (\< 4) SARC-F questionnaire.

    Time frame: Through study completion, an average of 1 year.

  4. Myostatin serum levels in patients with and without osteoporotic bone

    Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without osteoporotic bone.

    Time frame: Through study completion, an average of 1 year.

  5. Myostatin serum levels in patients with and without muscle atrophy

    Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without muscle atrophy.

    Time frame: Through study completion, an average of 1 year.

  6. Insulin-like growth factor 1 (IGF-1) serum levels in patients with positive and negative SARC-F questionnaire

    Mean ± standard error of the mean, median, and min-max range of circulating IGF-1 (µg/L) in patients with positive (= or \> 4) and negative (\< 4) SARC-F questionnaire.

    Time frame: Through study completion, an average of 1 year.

  7. Insulin-like growth factor 1 (IGF-1) serum levels in patients with and without osteoporotic bone

    Mean ± standard error of the mean, median, and min-max range of circulating IGF-1 (µg/L) in patients with and without osteoporotic bone.

    Time frame: Through study completion, an average of 1 year.

  8. Insulin-like growth factor 1 (IGF-1) serum levels in patients with and without muscle atrophy

    Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without muscle atrophy.

    Time frame: Through study completion, an average of 1 year.

  9. Frequency of intake of the different food categories in patients with positive and negative SARC-F questionnaire

    The percentage of patients with positive (= or \> 4) and negative (\< 4) SARC-F questionnaire who assume never/rarely and regularly the different food categories.

    Time frame: Within 24 hours of admission

  10. Frequency of intake of the different food categories in patients with and without osteoporotic bone

    The percentage of patients with and without osteoporotic bone who assume never/rarely and regularly the different food categories.

    Time frame: Through study completion, an average of 1 year.

  11. Frequency of intake of the different food categories in patients with and without muscle atrophy

    The percentage of patients with and without muscle atrophy who assume never/rarely and regularly the different food categories.

    Time frame: Through study completion, an average of 1 year.

  12. Inflammatory serum markers

    Mean ± standard error of the mean, median, and min-max range of circulating IL-6, IL-8, TNF-α in patients

    Time frame: Through study completion, an average of 1 year.

  13. Serum markers of bone metabolism

    Mean ± standard error of the mean, median, and min-max range of circulating FGF-21, GDF15, ST2 in patients

    Time frame: Through study completion, an average of 1 year.

Other outcomes

  1. Characterization of gut microbiota

    The "Next Generation Sequencing" technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to assess alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between individuals).

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers. J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):609-618. doi: 10.1002/jcsm.12567. Epub 2020 Mar 22. PubMed 32202056 ↗
  • Wong RMY, Wong H, Zhang N, Chow SKH, Chau WW, Wang J, Chim YN, Leung KS, Cheung WH. The relationship between sarcopenia and fragility fracture-a systematic review. Osteoporos Int. 2019 Mar;30(3):541-553. doi: 10.1007/s00198-018-04828-0. Epub 2019 Jan 4. PubMed 30610245 ↗
  • Kirk B, Al Saedi A, Duque G. Osteosarcopenia: A case of geroscience. Aging Med (Milton). 2019 Sep 8;2(3):147-156. doi: 10.1002/agm2.12080. eCollection 2019 Sep. PubMed 31942528 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.

Of 52 non-industry observational studies under Osteoarthritis, Hip, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 59. This study's planned 73 months is above that.

Counting every sponsor, half of 81 studies reached it within 53 months; a quarter within 13 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2021
First posted
Jan 29, 2021
StartActual
Nov 23, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04730622
Responsible party
Sponsor
First posted
Jan 29, 2021
Start date
Nov 23, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Gemma Di Pompo, M.Sc.
Contact
gemma.dipompo@ior.it
+39 0516366748
Nicola Baldini, M.D.
principal investigator · University of Bologna, Istituto Ortopedico Rizzoli

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion